date,title,source
Oct-31-18,Aytu BioScience to Report Fiscal First Quarter 2019 Results and Business Update,ACCESSWIRE
Nov-05-18,"Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra(R) XR",ACCESSWIRE
Nov-07-18,Aytu BioScience Reports 55% Sequential Revenue Growth in Q1 FY19; Adds Tuzistra(R) XR to Portfolio,ACCESSWIRE
Nov-07-18,Biotech Stocks and the Midterm Elections,ACCESSWIRE
